tiprankstipranks
Trending News
More News >
Synthomer PLC (GB:SYNT)
LSE:SYNT

Synthomer (SYNT) AI Stock Analysis

Compare
88 Followers

Top Page

GB:SYNT

Synthomer

(LSE:SYNT)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 5.2)
Rating:51Neutral
Price Target:
59.00p
▲(10.28% Upside)
Synthomer's overall stock score reflects significant financial challenges, with negative profitability and high leverage being major concerns. Technical analysis provides mixed signals, with short-term bullish momentum but longer-term bearish trends. Valuation is weak due to a negative P/E ratio. However, positive corporate events, such as insider buying and strategic appointments, offer some optimism for future prospects.
Positive Factors
Innovative Product Offerings
Synthomer's emphasis on innovative and high-performance products positions it well to meet evolving customer needs, supporting long-term growth.
Strategic Partnerships
Strategic partnerships enhance distribution and market reach, providing a durable competitive advantage and supporting revenue stability.
Focus on Sustainability
A focus on sustainability aligns with global trends, potentially increasing demand for Synthomer's products and improving its market position.
Negative Factors
High Debt Levels
High leverage can limit financial flexibility and increase risk, potentially impacting Synthomer's ability to invest in growth opportunities.
Negative Cash Flow
Negative cash flow suggests inefficiencies in operations and challenges in sustaining business activities without external financing.
Declining Profitability
Declining profitability indicates operational struggles and could hinder Synthomer's ability to reinvest in the business for future growth.

Synthomer (SYNT) vs. iShares MSCI United Kingdom ETF (EWC)

Synthomer Business Overview & Revenue Model

Company DescriptionSynthomer plc operates as a specialty chemicals company. It operates through four segments: Performance Elastomers, Functional Solutions, Industrial Specialities, and Acrylate Monomers. The company offers pressure sensitive adhesives, acrylic polymers, acrylic dispersions, saturants, release coatings, and other adhesives; water-based carboxylated styrene butadiene rubber, redispersible powder, flooring adhesive, and additives for construction applications; and impregnation binders, styrene butadiene copolymers, dispersions, polymer binders, and butadiene-based binders for textiles applications. It also provides binders for various carpets; synthetic binders for graphic, packaging, and specialty paper coating applications; paper coating additives and plastic pigments; binders, dispersions, water-based and solvent-borne resins, and other products for various coating applications; foamed bedding products and footwear; elastomeric modifiers for thermoplastics and friction components; reinforcement resins for rubber compounds; and latex for tire cord. In addition, the company offers compounds and aqueous curing pastes for carpets and other applications; acrylic monomers for enhancing the performance characteristics of polymer formulations; antioxidant products; latices for medical examination, clean room, food handling, chemotherapy drug handling, chemical laboratory, and medical device and balloon applications; and nitrile latex, which enhance performance of industrial and fabric-supported gloves. Further, it provides liquid polybutadienes, polyvinyl alcohol suspending agents, polyvinyl acetates, thermosetting resins, butyl ethyl propanediol, and inorganic materials for various industrial applications; and coalescing agents for enhancing the properties of coatings. The company was formerly known as Yule Catto & Co. plc and changed its name to Synthomer plc in 2012. Synthomer plc was founded in 1863 and is headquartered in London, the United Kingdom.
How the Company Makes MoneySynthomer generates revenue through the sale of its wide range of polymer products, which are sold primarily to industrial customers in various sectors including construction, textiles, and coatings. The company's revenue model is largely based on volume sales, with a focus on high-margin specialty products that command premium prices. Key revenue streams include the production of water-based emulsions and other specialty polymers, which are used in applications such as adhesives and paints. Additionally, Synthomer benefits from strategic partnerships with key players in its target markets, facilitating distribution and expanding its market reach. The company also invests in research and development to innovate new products that meet evolving customer needs, thereby enhancing its competitive position and driving sales growth.

Synthomer Financial Statement Overview

Summary
Synthomer's financial performance is under pressure with declining profitability, negative net income, and high leverage. The income statement, balance sheet, and cash flow statement all indicate significant challenges, including negative free cash flow and high debt levels.
Income Statement
45
Neutral
Synthomer's income statement shows a challenging financial position with declining profitability. The gross profit margin has deteriorated significantly from previous years, and both EBIT and net income are in negative territory, indicating operational struggles. The revenue growth rate is relatively flat, demonstrating a lack of top-line growth. The company needs to address these issues to improve its financial health.
Balance Sheet
50
Neutral
The balance sheet reflects a moderate financial position with high leverage. The debt-to-equity ratio has increased, indicating rising financial risk. Return on equity is negative due to net losses, which is concerning. However, the equity ratio remains above 40%, showing some level of financial stability. Synthomer needs to manage its liabilities and improve profitability to enhance its balance sheet strength.
Cash Flow
40
Negative
The cash flow statement reveals significant pressure, with negative free cash flow and operating cash flow in the latest period. The free cash flow growth rate is negative, showing a decline in cash generation. Additionally, the operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting income to cash. Synthomer must improve its cash flow management to ensure long-term sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.86B1.99B1.97B2.33B2.14B1.64B
Gross Profit336.90M337.70M307.30M281.00M569.70M336.70M
EBITDA70.30M83.00M113.40M139.40M394.40M254.50M
Net Income-83.60M-72.60M-67.00M-32.50M208.70M3.10M
Balance Sheet
Total Assets2.45B2.54B2.71B3.15B2.55B2.13B
Cash, Cash Equivalents and Short-Term Investments266.40M225.80M371.30M227.70M505.30M201.80M
Total Debt960.60M878.70M926.30M1.30B663.00M719.00M
Total Liabilities1.46B1.43B1.54B2.11B1.52B1.50B
Stockholders Equity983.70M1.09B1.15B1.02B1.02B615.00M
Cash Flow
Free Cash Flow-82.70M-124.10M66.00M45.00M193.20M134.90M
Operating Cash Flow14.90M-33.50M150.00M135.80M275.40M188.70M
Investing Cash Flow-70.60M-61.70M107.70M-850.10M-78.60M-365.80M
Financing Cash Flow44.80M-45.90M-90.90M414.50M118.50M273.20M

Synthomer Technical Analysis

Technical Analysis Sentiment
Negative
Last Price53.50
Price Trends
50DMA
59.16
Negative
100DMA
59.91
Negative
200DMA
75.15
Negative
Market Momentum
MACD
-1.73
Positive
RSI
34.49
Neutral
STOCH
10.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNT, the sentiment is Negative. The current price of 53.5 is below the 20-day moving average (MA) of 59.53, below the 50-day MA of 59.16, and below the 200-day MA of 75.15, indicating a bearish trend. The MACD of -1.73 indicates Positive momentum. The RSI at 34.49 is Neutral, neither overbought nor oversold. The STOCH value of 10.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SYNT.

Synthomer Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
£570.88M20.536.22%9.48%0.58%61.58%
65
Neutral
£3.81B27.226.17%3.45%2.36%-13.99%
64
Neutral
£918.27M-16.323.37%1.34%-11.78%-92.61%
63
Neutral
£287.77M31.173.48%2.44%-4.71%86.21%
62
Neutral
£201.98M287.500.60%2.00%15.56%-92.94%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
51
Neutral
£87.50M-1.05-7.26%-4.41%2.29%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:SYNT
Synthomer
53.50
-95.30
-64.05%
GB:CRDA
Croda International
2,728.00
-359.62
-11.65%
GB:ELM
Elementis
161.60
10.30
6.81%
GB:ESNT
Essentra
101.00
-18.30
-15.34%
GB:VCT
Victrex
656.00
-243.93
-27.11%
GB:ZTF
Zotefoams
414.00
129.80
45.67%

Synthomer Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A Transactions
Synthomer Lifts Margins and Cash Flow Despite Softer Demand and Tariff Hit
Positive
Jan 29, 2026

Synthomer expects 2025 revenue of about £1.74bn and EBITDA of £135m–£138m for its continuing operations, slightly down on 2024 but in line with expectations, as cost-cutting and a shift toward higher-margin speciality solutions helped offset weaker demand following global tariff changes. The group generated positive free cash flow, reduced net debt to around £575m, maintained covenant leverage comfortably within limits, and reported margin gains across its portfolio, supported by progress in Adhesive Solutions, improving medical glove volumes, and ongoing divestments to deleverage and simplify the business, positioning it for earnings growth in 2026 even without a strong market recovery.

The most recent analyst rating on (GB:SYNT) stock is a Hold with a £52.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Synthomer Announces Receivables Purchasing Agreement to Enhance Financial Flexibility
Positive
Dec 18, 2025

Synthomer has entered a trade receivables purchasing arrangement with Rainbow State Limited, a subsidiary of its major shareholder KLK Group. This temporary arrangement will provide Synthomer with short-term financial flexibility and ensure sufficient banking covenant headroom. Under this agreement, KLK will purchase approximately £50 million of trade receivables, aligning with the firm’s prudent funding strategy, and the terms have been evaluated as fair by an independent advisor. This move highlights Synthomer’s proactive financial management and collaboration with key stakeholders to maintain stability during the year-end.

The most recent analyst rating on (GB:SYNT) stock is a Hold with a £59.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
Synthomer Announces Board Changes to Strengthen Governance
Neutral
Dec 12, 2025

Synthomer plc announced changes to its Board, with Ian Tyler and Roberto Gualdoni stepping down as independent Non-Executive Directors. Janet Ashdown will succeed Ian as Senior Independent Director, and Jonathan Silver will become Chair of the Audit Committee. These changes are part of Synthomer’s ongoing efforts to align with the UK Corporate Governance Code and enhance its leadership structure, potentially impacting its governance and strategic direction.

The most recent analyst rating on (GB:SYNT) stock is a Hold with a £59.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Other
Synthomer CEO Invests in Company Shares
Positive
Nov 12, 2025

Synthomer PLC announced that its CEO, Michael Willome, has purchased 63,000 ordinary shares of the company at a price of £0.4918 per share, totaling £30,983.40. This transaction, conducted on the London Stock Exchange, signifies a potential vote of confidence in the company’s future prospects and may impact stakeholder perception positively.

The most recent analyst rating on (GB:SYNT) stock is a Hold with a £54.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 07, 2025